secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sagimet Biosciences Inc. (SGMT)
CIK:        0001400118
Form:       8-K
Filed at:   2026-04-21T23:59:59+00:00
Accession:  0001104659-26-045629
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Sagimet Biosciences CMO Eduardo Martins retires; Andreas Grauer appointed as replacement
--------------------------------------------------------------------------------

- CMO Eduardo Martins retired effective April 20, 2026; will remain as external scientific advisor.
- Andreas Grauer, M.D., appointed as new CMO, effective April 20, 2026.
- Dr. Grauer previously served as CMO at Omeros Corporation (Oct 2023–Apr 2026) and earlier at Federation Bio, Corcept, Amgen.
- He also serves as Associate Professor of Medicine at University of Heidelberg Medical School.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1400118/000110465926045629/0001104659-26-045629-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1400118/000110465926045629/tm2612312d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-045629

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer